Biotech Startups

Golgenia is a biotech startup developing small-molecule inhibitors that target Golgi-based "glyco-oncogenes" — proteins that disrupt glycosylation and drive tumor development. Its research aims to create anticancer therapies, including for tumors that are non-responsive to current treatments, with an initial drug series acting on glycosphingolipid biosynthesis.

1 investor

GoodCap Pharmaceuticals develops drug candidates targeting disorders driven by neuroinflammation, with a lead candidate (GCAP001) combining two molecule classes to reduce inflammatory biomarkers linked to psychiatric and neurodegenerative conditions. Its initial focus is on treating PTSD.

1 investor

Goodfellow supplies advanced specialist materials, including metals, alloys, ceramics, polymers, and compounds, alongside custom manufacturing and modification services for scientific and industrial customers worldwide. The company also provides micromanufacturing capabilities through its 2024 acquisition of Potomac Photonics.

1 investor

GoodGut develops intellectual property based on the study of individuals' gut microbiota, which plays a role in intestinal immunity and the development of digestive diseases. The company aims to provide diagnostic solutions for digestive conditions to the healthcare system.

1 investor

Gordion uses AI-driven analysis of patient-derived data to validate oncology drug targets before clinical development. The company serves pharmaceutical and biotech organizations developing cancer treatments.

1 investor

GRA Nutra develops fermentation-based and algae-derived formulated ingredients, supplying natural colors, carotenoids, vitamins, and specialty ingredients to the food & beverage, supplement, and pet food industries. Founded in 2021, the company combines fermentation and algae production technologies with formulation and commercial expertise.

1 investor

Grabis is a South Korean biotechnology company that develops magnetic bead technologies for nucleic acid and protein purification. Its products support DNA/RNA purification for NGS library preparation, protein purification, and on-site nucleic acid extraction.

1 investor

Gradalis develops Vigil, a patient-specific immunotherapy studied in research and clinical trials for treating ovarian cancer, with potential use in other solid tumors. The therapy can be used on its own or alongside other cancer treatments.

1 investor

Grandomics develops third-generation sequencing services and precision genomic medicine solutions for medical diagnostics, plant and animal breeding, and species conservation. The company applies long-read sequencing technology and computational methods to assemble complete genomes and address applications in medicine, crop improvement, and biodiversity protection.

1 investor

Grantscout is a grant-writing and non-dilutive funding advisory service that develops expert, human-written proposals and multi-year funding strategies for startups and research-driven companies. It targets technical and scientific ventures seeking funding from agencies such as NIH, ARPA-H, NSF, DoD, DoE, USDA, and NOAA.

1 investor

GRAVL provides digital infrastructure software for research facilities and core labs, enabling scientists to access scientific tools and services. The platform streamlines operations and management for academic and research institutions.

1 investor

Great Bay Bio applies systems biology—combining biology, engineering, and computation—to model the complexity of health and disease and support precision medicine. It works with biotech and pharma companies to pursue biomedical, technological, and business-model innovation.

1 investor

Green Elephant Biotech manufactures 96-well microplates and related lab consumables for life science research. The company sells through authorized distributors across Europe and the United States, as well as directly to labs.

1 investor

GreenGrahi uses Black Soldier Fly biotechnology to convert organic waste into ingredients for animal feed, pet food, and agriculture. The company develops insect-based products and processes aimed at creating a sustainable alternative to conventional organic waste management.

1 investor

Green Spot develops fermentation-based ingredients for industrial use by translating natural biological processes into scalable production systems. The company serves ingredient and formulation companies seeking sustainable alternatives to extractive or scarce resources.

1 investor

Greenfluidics designs living façades—integrated biological systems for building exteriors—that bring nature into urban environments. The company serves architects, developers, institutions, and global brands seeking to reconnect cities with natural spaces.

1 investor

Greengine develops technology to capture carbon emissions and support carbon sequestration, helping organizations reduce their carbon footprint and meet net-zero goals. The company focuses on sustainability and climate solutions, with an orientation toward India and global markets.

1 investor

GreenJay Therapeutics is a late-stage pharmaceutical company reformulating existing drugs to improve clinical outcomes for hematological diseases. Its lead product, Bulanta, is a new intravenous busulfan formulation that removes a Class 2 solvent to reduce toxicity, initially targeting chronic myelogenous leukemia patients undergoing stem cell transplantation.

1 investor

Green Sage Prebiotics develops natural prebiotic solutions to reduce infections and improve health in aquaculture (shrimp and salmon), pets, and humans. The company addresses antibiotic-resistant diseases and premature mortality in farmed seafood, as well as recurring infections in human and animal populations.

1 investor

GreenVenus develops improved crop varieties including leafy greens, grapes, berries, avocados, beans, and lentils using breeding technologies focused on traits such as longer shelf-life, improved flavor, and higher yields.

1 investor

Grenova develops laboratory technology for washing and reusing pipette tips and microwell plates, aimed at labs seeking to reduce consumable waste and costs. The company operates in the life sciences lab equipment and sustainability space.

1 investor

Grey Matter Neurosciences develops transcranial focused ultrasound systems combined with drug therapies to treat mood and cognitive disorders in older adults, with an initial focus on non-invasive neuromodulation outside hospital settings.

1 investor

Grown Alchemist develops high-performance skincare products that combine botanically-sourced ingredients with biotechnology, designed for consumers focused on skin health and wellness. The company operates flagship stores in Melbourne, London, and Hong Kong, and distributes through premium retailers globally.

1 investor

2NA FISH develops a spatial RNA detection platform using nanostructure-enhanced probes for oncology research and pathology workflows. The platform combines brightfield RNA biomarker analysis on standard fluorescence microscopes with AI-powered software for quantification and cell-level readouts.

1 investor